Larvol Delta - Biond-Biologics-and-Sano-Enter-into-Global-Licensing-Agreement-for-BND22-a-Novel-Immune-Checkpoint-Inhibitor-Targeting-the-ILT2-Receptor

BND-22 - Biond Biologics, Sanofi

https://www.prnewswire.com/news-releases/biond-biologics-and-sanofi-enter-into-global-licensing-agreement-for-bnd-22-a-novel-immune-checkpoint-inhibitor-targeting-the-ilt2-receptor-301206200.html

Jan 12, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev